Lkit Therapeutics: Exploiting Synethtic Lethality to Target p53 Mutant Cancers Using First-In-Class Potent and Selective Small Molecule Inhibitors of Lipid Kinases PI5P4Kα/β.
Yale Lifesciences Pitchfest 2019
12/06/2019
Lkit Therapeutics: Exploiting Synethtic Lethality to Target p53 Mutant Cancers Using First-In-Class Potent and Selective Small Molecule Inhibitors of Lipid Kinases PI5P4Kα/β.
